What is Applied Proteomics?
Applied Proteomics, Inc. operates at the intersection of biotechnology and clinical diagnostics, focusing on the development of non-invasive, protein-based tests. Its flagship product, the SimpliPro Colon Test, represents a significant advancement in colorectal wellness assessment. By analyzing 11 specific protein markers, the test provides healthcare providers with a comprehensive risk profile for esophageal cancer and advanced adenoma. This diagnostic solution is engineered to integrate seamlessly into routine clinical workflows, thereby addressing the critical challenge of patient adherence to traditional colonoscopy procedures. The company's market position is defined by its commitment to enhancing early detection capabilities through high-precision, blood-based biomarker analysis.
How much funding has Applied Proteomics raised?
Applied Proteomics has raised a total of $54.5M across 3 funding rounds:
Series A
$4M
Series B
$22.5M
Series C
$28M
Series A (2007): $4M, investors not publicly disclosed
Series B (2012): $22.5M led by Domain Associates and Vulcan Capital Management
Series C (2013): $28M supported by Domain Associates, Vulcan Capital Management, and Genting Berhad
Key Investors in Applied Proteomics
Domain Associates
A specialized venture capital firm with a long-standing history in the life sciences sector, focusing on biopharmaceutical and diagnostic innovation.
Vulcan Capital Management
A diversified private equity firm that targets middle-market assets and strategic growth opportunities across various high-value sectors.
Genting Berhad
A prominent multinational holding company with a diverse portfolio, providing strategic capital to support long-term enterprise development.
What's next for Applied Proteomics?
With the support of its latest major strategic investment, Applied Proteomics is well-positioned to accelerate the commercialization of its diagnostic portfolio. The company is expected to focus on expanding its clinical footprint, potentially scaling its sales and distribution infrastructure to meet the growing demand for advanced cancer risk assessment tools. Furthermore, the capital infusion will likely support ongoing research and development efforts aimed at broadening the utility of its protein-marker technology. As the firm transitions into its next phase of growth, the strategic alignment with its existing investor base will be pivotal in navigating the regulatory and competitive landscape of the global diagnostics market, ultimately aiming to improve patient outcomes through early and accurate intervention.
See full Applied Proteomics company page
